BioNexus Financial Statements From 2010 to 2026

BioNexus Gene Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 6.7 M 12 M 4.3 M Slightly volatile Total Current Liabilities 1.5 M 2.2 M 962.8 K Slightly volatile Accounts Payable 1.4 M 1.7 M 958.4 K Slightly volatile Cash 5.3 M 5 M 1.8 M Slightly volatile Cash And Short Term Investments 5.3 M 5 M 1.8 M Slightly volatile Common Stock Shares Outstanding 1.2 M 2 M 983.4 K Slightly volatile Liabilities And Stockholders Equity 6.7 M 12 M 4.3 M Slightly volatile Total Liabilities 1.6 M 2.4 M 1 M Slightly volatile Total Current Assets 4.9 M 8.5 M 3.1 M Slightly volatile Common Stock 10.4 M 19.9 M 6.8 M Slightly volatile Other Current Liabilities 195.5 K 271.2 K 611.3 K Slightly volatile Other Liabilities 34.3 K 32.7 K 13.3 K Slightly volatile Property Plant And Equipment Net 1.3 M 2 M 861.3 K Slightly volatile Non Current Assets Total 2 M 3.5 M 1.3 M Slightly volatile Net Receivables 1.8 M 1.8 M 1 M Slightly volatile Short Term Investments 1.7 M 3.2 M 1 M Slightly volatile Non Current Liabilities Total 192.9 K 183.7 K 60.3 K Slightly volatile Inventory 860.4 K 1.6 M 525.8 K Slightly volatile Other Current Assets 68.2 K 96.8 K 90.7 K Slightly volatile Property Plant Equipment 961.7 K 1.9 M 825.2 K Slightly volatile Short and Long Term Debt Total 123.5 K 242.1 K 106.3 K Slightly volatile Capital Lease Obligations 121.4 K 242.1 K 105.4 K Slightly volatile Net Invested Capital 6.5 M 9.6 M 4.1 M Slightly volatile Long Term Investments 812.6 K 1.5 M 443.2 K Slightly volatile Capital Stock 12.6 M 19.9 M 9.8 M Slightly volatile Net Working Capital 4.3 M 6.3 M 2.8 M Slightly volatile Short Term Debt 39.6 K 58.4 K 29.6 K Slightly volatile Property Plant And Equipment Gross 2 M 2.9 M 1.2 M Slightly volatile Current Deferred Revenue 49.8 K 86.3 K 62.4 K Very volatile Common Stock Total Equity 8.6 M 9.7 M 10.6 M Slightly volatile Retained Earnings Total Equity 1.3 M 1.7 M 1 M Slightly volatile Non Current Liabilities Other 58.2 K 59.3 K 73.9 K Slightly volatile Other Assets 0.8 0.9 0.9824 Slightly volatile
BioNexus Gene Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 184.9 K 176.1 K 61.9 K Slightly volatile Other Operating Expenses 7.1 M 12.7 M 4.6 M Slightly volatile Total Revenue 7.6 M 10.9 M 4.4 M Slightly volatile Gross Profit 1.1 M 1.5 M 652 K Slightly volatile Cost Of Revenue 6.5 M 9.5 M 3.7 M Slightly volatile Selling General Administrative 1.5 M 2.3 M 879.2 K Slightly volatile Reconciled Depreciation 104.8 K 176.1 K 74.9 K Slightly volatile Interest Income 119 K 169.8 K 82.2 K Slightly volatile Selling And Marketing Expenses 1.4 M 2.3 M 833.4 K Slightly volatile Research Development 41 K 42.8 K 53 K Slightly volatile
BioNexus Gene Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 5.5 M 5.2 M 1.5 M Slightly volatile End Period Cash Flow 2.3 M 3.3 M 1.4 M Slightly volatile Depreciation 94.3 K 176.1 K 62.4 K Slightly volatile Change Receivables 544.7 K 666.1 K 473.5 K Slightly volatile Exchange Rate Changes 48.7 K 54.8 K 59.8 K Slightly volatile Dividends Paid 46.6 K 78.3 K 23.5 K Slightly volatile Cash Flows Other Operating 55.6 K 58.5 K 357.7 K Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 0.57 0.6 850 Slightly volatile Days Sales Outstanding 76.56 69.74 37.5194 Slightly volatile Average Payables 1.2 M 1.5 M 906.1 K Slightly volatile Capex To Depreciation 1.62 1.7 10.5675 Slightly volatile EV To Sales 0.0945 0.0994 846 Slightly volatile Inventory Turnover 6.1 5.33 4.6347 Slightly volatile Days Of Inventory On Hand 98.57 70.9 219 Slightly volatile Payables Turnover 3.48 4.92 2.7275 Slightly volatile Sales General And Administrative To Revenue 0.23 0.24 0.8445 Slightly volatile Average Inventory 488.4 K 952 K 443.3 K Slightly volatile Research And Ddevelopement To Revenue 0.0058 0.0057 0.0056 Very volatile Capex To Revenue 0.0261 0.0274 1.4007 Slightly volatile Cash Per Share 1.5 2.21 1.2142 Slightly volatile Days Payables Outstanding 152 76.76 259 Slightly volatile Current Ratio 6.82 4.38 3.947 Slightly volatile Receivables Turnover 13.28 6.92 28.9661 Slightly volatile Debt To Equity 0.0333 0.0291 0.0415 Slightly volatile Capex Per Share 0.19 0.15 0.3073 Slightly volatile Average Receivables 2.3 M 1.4 M 2.8 M Slightly volatile Revenue Per Share 4.2 4.8 3.0699 Slightly volatile Interest Debt Per Share 0.12 0.15 0.1307 Slightly volatile Debt To Assets 0.0286 0.0232 0.0371 Slightly volatile Graham Number 6.5 6.95 5.2765 Slightly volatile Operating Cycle 156 141 251 Slightly volatile Days Of Payables Outstanding 152 76.76 259 Slightly volatile Ebt Per Ebit 0.8 0.91 0.9779 Slightly volatile Long Term Debt To Capitalization 0.0309 0.0348 0.0379 Slightly volatile Total Debt To Capitalization 0.0317 0.0284 0.0395 Slightly volatile Debt Equity Ratio 0.0333 0.0291 0.0415 Slightly volatile Quick Ratio 6.41 3.56 3.6796 Slightly volatile Net Income Per E B T 0.71 0.9 0.9415 Slightly volatile Cash Ratio 4.47 2.58 2.5714 Slightly volatile Days Of Inventory Outstanding 98.57 70.9 219 Slightly volatile Days Of Sales Outstanding 76.56 69.74 37.5194 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 0.63 0.99 0.5149 Slightly volatile Fixed Asset Turnover 3.39 4.92 2.6444 Slightly volatile Debt Ratio 0.0286 0.0232 0.0371 Slightly volatile Price Sales Ratio 0.57 0.6 850 Slightly volatile Asset Turnover 0.58 0.82 0.4617 Slightly volatile Gross Profit Margin 0.28 0.16 0.4455 Slightly volatile
BioNexus Gene Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 5.5 M 5.7 M 133.9 M Slightly volatile Enterprise Value 898.4 K 945.6 K 132 M Slightly volatile

BioNexus Fundamental Market Drivers

BioNexus Upcoming Events

About BioNexus Gene Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:

How To Invest In BioNexus Details

Is BioNexus Stock a good investment? Details

What is BioNexus Gene's Net Worth? Details

Largest Specialty Chemicals Companies View

Largest Basic Materials Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Technical Analysis Details